Recursion is poised to be a leader in the technological revolution of pharmaceutical companies, providing a real-world application to AI-powered tools, reducing the time and budget required for ...
“Our platforms at Recursion really focused on application of biology, hit discovery, target discovery,” he said. “We've been building that for over a decade and our colleagues at Exscientia ...
Ultimately, the success of edge AI hinges on the development of compelling applications that consumers ... Back in August, ...
Recursion announced that the UK Medicines and Healthcare Products Regulatory Agency has cleared a clinical trial application for a Phase 1 ...
Recursion was able to use its artificial intelligence ... The Food and Drug Administration cleared the investigational new ...
Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders ...
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback